TY - JOUR
T1 - “Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: A multicenter phase II trial of the Southern Italy Cooperative Oncology Group”.
AU - Palmeri, Sergio
AU - Putzu, Carlo
AU - Comella, Pasquale
AU - Greco, Ettore
AU - Franco, Luca
AU - Vessia, Giacomo
AU - Lorusso, Vito
AU - Leo, Silvana
AU - Cannone, Michele
AU - Mancarella, Sergio
AU - Casaretti, Rossana
AU - Maiorino, Luigi
AU - Sandomenico, Claudia
AU - Massidda, Bruno
AU - Roselli, Mario
PY - 2009
Y1 - 2009
N2 - Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade ≥3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients. Conclusions: Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
AB - Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade ≥3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients. Conclusions: Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
KW - Fluorouracil
KW - Gastric cancer
KW - Irinotecan
KW - Oxaliplatin
KW - Triplet regimen
KW - Fluorouracil
KW - Gastric cancer
KW - Irinotecan
KW - Oxaliplatin
KW - Triplet regimen
UR - http://hdl.handle.net/10447/45319
M3 - Article
VL - 64
SP - 893
EP - 899
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
ER -